Rabbit Recombinant Monoclonal Cytokeratin 13 antibody. Suitable for IHC-P, WB and reacts with Human samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
IHC-P | IP | Flow Cyt | WB | |
---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/250 | Notes Perform heat-mediated antigen retrieval before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/2000 - 1/10000 | Notes - |
Select an associated product type
Type 1 keratin (Probable). Maintains postnatal tongue mucosal cell homeostasis and tissue organization in response to mechanical stress, potentially via regulation of the G1/S phase cyclins CCNE1 and CCNE2 (By similarity).
Cytokeratin-13, Keratin-13, CK-13, K13, KRT13
Rabbit Recombinant Monoclonal Cytokeratin 13 antibody. Suitable for IHC-P, WB and reacts with Human samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
Species cross reactivity determined by western blot only
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Cytokeratin 13 also known as KRT13 or CK13 is a type I intermediate filament protein weighing approximately 44 kDa. It is one of the cytokeratin types that plays a critical role in the mechanical stability and integrity of epithelial cells. Cytokeratin 13 is expressed in the stratified squamous epithelium particularly in the upper layers of non-cornified epithelia which include the esophagus tongue and cervix. This protein forms heteropolymers with type II keratins contributing to the cytoskeletal filament network within epithelial cells.
This protein participates in maintaining the structural framework and dynamics within epithelial tissues. As part of the cytoskeletal complex cytokeratin 13 supports cellular resilience against mechanical stress. It interacts with other cytokeratins contributing to the formation of a robust keratin filament network essential for epithelial cell function and differentiation. Its expression and regulation are key to the homeostasis of the tissues where it is found ensuring proper cell division and tissue integrity.
Cytokeratin 13 integrates into epithelial cell differentiation and repair processes. It is involved in the epithelial-mesenchymal transition (EMT) pathway important for tissue development wound healing and cancer metastasis. During the EMT process cytokeratin 13 often works alongside proteins like E-cadherin and Vimentin mediating changes in epithelial cell architecture and polarity. This modulation is essential for cellular plasticity and response to environmental cues.
Cytokeratin 13 has associations with certain epithelial tissue abnormalities such as oral squamous cell carcinoma and a subgroup of inherited blistering diseases like epidermolysis bullosa. In oral squamous cell carcinoma dysregulation of cytokeratin 13 expression may indicate tumor progression and metastasis. In epidermolysis bullosa mutations affecting keratin interactions including those with other keratins like cytokeratin 14 can lead to fragile skin and mucosal surfaces resulting in increased susceptibility to physical damage and impaired healing.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
False colour image of Western blot: Anti-Cytokeratin 13 antibody [EPR3672] staining at 1/2000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab133340 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line Human KRT13 knockout A-431 cell line ab269483 (knockout cell lysate Human KRT13 knockout A-431 cell lysate ab269647). To generate this image, wild-type and Krt13 knockout A431 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.
All lanes: Western blot - Anti-Cytokeratin 13 antibody [EPR3672] (ab133340) at 1/2000 dilution
Lane 1: Wild-type A431 cell lysate at 20 µg
Lane 2: KRT13 knockout A431 cell lysate at 20 µg
Lane 2: Western blot - Human KRT13 knockout A-431 cell line (Human KRT13 knockout A-431 cell line ab269483)
Performed under reducing conditions.
Predicted band size: 50 kDa
Observed band size: 51 kDa
All lanes: Western blot - Anti-Cytokeratin 13 antibody [EPR3672] (ab133340) at 1/2000 dilution
Lane 1: A431 cell lysate at 10 µg
Lane 2: HACAT cell lysate at 10 µg
All lanes: HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 50 kDa
Observed band size: 50 kDa
Immunohistochemical analysis of Cytokeratin 13 in formalin fixed, paraffin embedded Human squamous cell cervical carcinoma tissue stainied with ab133340 at a 1/100 dilution.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Immunohistochemical analysis of Cytokeratin 13 in formalin fixed, paraffin embedded Human transitional cell carcinoma of urinary bladder tissue stainied with ab133340 at a 1/100 dilution.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Immunohistochemical analysis of paraffin embedded Human Glioma tissue using ab133340 showing -ve staining.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Immunohistochemical analysis of paraffin embedded Human Breast carcinoma tissue using ab133340 showing -ve staining.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Immunohistochemical analysis of paraffin embedded normal Human tonsil squamous cells tissue using ab133340 showing +ve staining.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com